Aquestive Therapeutics, Inc. (AQST) income statement
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.71−0.07 (-1.98%)
Close on Nov 19, 2026Market cap $465.02MP/E –Yield –
Aquestive Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 67.0%
- Operating margin
- -97.5%
- Net margin
- -144.6%
- Return on equity, FY2025
- 178.6%
Financial strength
- Current ratio
- 7.19
- Debt to equity
- -0.90
- Debt to assets
- 38.4%
- Cash to current liabilities
- 597.7%
Valuation
- P/E ratio
- –
- Price to sales
- 8.60
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?